Links:
Links:
While myositis-specific autoantibodies (MSAs) and myositis-associated autoantibodies (MAAs) may have prognostic value through their clinical associations, many patients will not have them and overall, they are poorly predictive of a malignancy risk.
Read Article
Links:
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com
A population based Swedish study of birth records shows that antibiotic exposure in first three years of life to be associated with a future risk of JIA, although infections during fetal
Almost three years ago to the day, I did a podcast entitled, "I wanna new drug." As I go over this week's podcast, I want to say it again. I want a new drug safe enough to use during pregnancy, for PMR, for GVHD, and more. I'm going to cover these, and other topics including lupus, COVID
Read Article
Inclusion body myositis (IBM) patients tend to be older than those with idiopathic inflammatory myositis (IIM), but the scope of disease beyond their myositis is not appreciated. Now, a population-based, case-control study suggests both a lower overall survival and high comorbidity burden in
Read Article
Patients with dermatomyositis who were positive for a myositis-specific antibody had a much higher incidence of and mortality associated with Pneumocystis jirovecii infection than patients with other antibody-negative idiopathic inflammatory myopathies, Chinese researchers found.
Read Article
Links:
Dr. John Cush @RheumNow( View Tweet )
This week: high science that affect future treatments; breakthrough infections in our patients, and what's up with that; and soon your radiologist is going to be replaced by AI. This and more in our review of the news and journal articles from the past week.
Read Article
Links:
Dr. John Cush @RheumNow( View Tweet )
Links:
Links:
The Journal of Autoimmunity reports that anti-HMRCR antibody positive, necrotizing myositis patients frequently have cutaneous lesions, moreso than previously reported.
Anti-3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) antibodies have been linked to the immune-mediated
Read Article
Links:
Dr. John Cush @RheumNow( View Tweet )
Links:
The U.S. Food and Drug Administration (FDA) has approved Octagam 10% [Immune Globulin Intravenous (Human)], as the first and only intravenous immunoglobulin (IVIg) formulation to be approved for adult dermatomyositis (DM).
The manufacturer, Octapharma USA, received
Read Article
Links:
Dr. John Cush @RheumNow( View Tweet )
2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related. Below, are our top news items
Read Article
Links:
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com - a website for rheumatologists, by rheumatologists.
We love Rheumatology!
CDC study from 33 sites, 25 states showed vaccine efficacy (against Sx COVID) in HCP was 82% with ONEdose
Researchers from the University of Cincinnati Gardner Neuroscience Institute will present data on a new treatment for Pompe disease at the American Academy of Neurology on April 20th; the results show that treatment with avalglucosidase alfa yielded substantial clinical improvements and a more
Read Article
Dr. Jack Cush serves up this week's news and articles from RheumNow.com.
Read Article
Winning is everything – in football and in medicine. Rheumatologists have achieved many successes but still struggle to win against a handful of rheumatic foes. This retrospective examines past wins and losses and helps us to look ahead to a new season.
Read Post
